Curcumin, a naturally occurring lipophilic molecule can exert multiple and diverse bioactivities. However, its limited aqueous solubility and extensive presystemic metabolism restrict its bioavailability. Curcumin phytosomes were prepared by a simple solvent evaporation method where free fl owing powder was obtained in addition to a newly developed semisolid formulation to increase curcumin content in soft gels. Phytosomal powder was characterized in terms of drug content and zeta potential. Thirteen diff erent soft gel formulations were developed using oils such as Miglyol 812, castor oil and oleic acid, a hydrophilic vehicle such as PEG 400 and bioactive surfactants such as Cremophor EL and KLS P 124. Selected formulations were characterized in terms of curcumin in vitro dissolution. TEM analysis revealed good stability and a spherical, self-closed structure of curcumin phytosomes in complex formulations. Stability studies of chosen formulations prepared using the hydrophilic vehicle revealed a stable curcumin dissolution patt ern. In contrast, a dramatic decrease in curcumin dissolution was observed in case of phytosomes formulated in oily vehicles.
INTRODUCTION
Curcumin (CUR) found in the turmeric rhizomes can exert multiple and diverse bioactivities, including antioxidant, antitumor, anti-inflammatory, antidiabetic, antirheumatic, wound healing, antiviral, hepatoprotective, and anti-HIV activity (1) . Despite the potential biological eff ects of CUR, poor bioavailability in both rodents and humans, as reported in several pharmacokinetic studies (2) , demands high doses to reach therapeutic drug levels. Detectable serum levels were not achieved until doses of up to 3.6 g were used; consequently, a 3.6 g daily dose of oral CUR was used in the phase II clinical trial in patients with advanced colorectal cancer (3) .
AHMED N. ALLAM 1, * IBRAHIM A. KOMEIL 2 OSSAMA Y. ABDALLAH 1 Keeping in mind the promise of CUR as a therapeutically active agent and its poor oral absorption due to its limited aqueous solubility and extensive presystemic metabolism, it is necessary to develop a new formulation of CUR that could augment its oral absorption and enhance its therapeutic activity.
To improve the bioavailability of CUR, numerous approaches and technologies have been investigated over the past decades, including the use of solid dispersion (4), copolymeric micelles (5) , polymeric nanoparticles (6) , lipid based nanoparticles (7), self microemulsion (8) , liposomes (9) and complexation with phospholipids (10, 11) . All these approaches are expected to provide bioavailability enhancement and improved absorption in the intestinal tract.
Phytosomes are considered to be a safe and convenient delivery system, able to enhance oral bioavailability of poorly water soluble drugs. Their safety is related to the similarity between their structural components and the lipid content of mammalian cell membranes (12) (13) (14) . Phytosomes show a bett er stability profi le than liposomes due to the unique chemical bond interaction between phospholipid molecules and polyphenolic compounds (15) .
Meriva
TM of Indena Company is the only patented commercial product containing CUR formulated as a complex with phospholipids (16). It is available as a hard gelatin capsule containing 100 mg of CUR.
Soft gel technology could be utilized to improve oral absorption of CUR phytosomes, along with increasing the available dose. The soft gel dosage form has several advantages over other oral dosage forms, such as delivering a liquid matrix intended to solubilize and enhance oral bioavailability of a poorly soluble compound. In addition, it can protect the encapsulated compound against oxygen and light, and it is able to readily disperse in gastric juices. From the industrial point of view, this technology is benefi cial since it minimizes potential generation of dust during manufacturing and thereby improves the safety of production personnel (17, 18). Soft gels have received enormous consumer acceptance due to the ease of swallowing and unpleasant taste masking (19) . Use of formulations containing natural and/or synthetic lipids in addition to excipients with reported bioactive eff ect on metabolism could provide a good opportunity to manage the poor gastrointestinal absorption associated with CUR.
The main goal of this study was to prepare a CUR phospholipid complex in dry powder using a simple method, and then formulate it in a fi nal dosage form utilizing the advantages of soft gel technology. Moreover, development of a new semisolid fi ll formulation was aimed to increase drug loading in order to improve patient compliance and adherence. The formulated CUR phytosomes were characterized in terms of in vitro dissolution behavior and selected formulations were further assessed for diff erent physicochemical properties before and aft er storage.
EXPERIMENTAL

Materials
Curcumin powder was purchased from Shenzhen Chemrider, China. The soy phosphatidylcholine (SPC) phospholipid, Lipoid S 100, was kindly supplied by Lipoid Co., Ger-many. Kollisolv P 124 (KLS P124), Polyoxyl 35 castor oil (CRM EL) and Polyoxyl 40 hydrogenated castor (CRM RH40) were purchased from BASF, USA. Soya bean oil and capric/ caprilic triglyceride (Miglyol 812) were purchased from Gatt efossé Corp., USA. Polyethylene glycol 400 (PEG 400) was a sample gift from Galaxy, India. Colloidal silicon dioxide (Aerosil 200) and sodium lauryl sulphate were purchased from Evonik Degussa, UK. All other reagents and chemicals were of analytical grade.
Preparation of the curcumin-phospholipid complex (CUR-SPC complex)
In the preparation of the curcumin-phospholipid complex, the method reported by Maiti et al. (10) and Gupta el al. (11) was utilized with slight modifi cation. Briefl y, CUR and SPC S 100 in a molar ratio of 1:1 were dissolved in 20 mL of dichloromethane in a round bott om fl ask. This mixture was refl uxed for 2 h at room temperature, stirred by a magnetic stirrer (IKA T25, Germany) and poured into a beaker containing colloidal silicon dioxide powder (Aerosil 200) in the same amount as SPC. The solvent was evaporated by placing the beaker in a controlled temperature water bath and using a mixer (IKA T25, Germany) at 40-45 °C for 4 hours.
Analysis of CUR content in the prepared CUR-SPC complex
Sample of 100 mg of test powder was sonicated in 100 mL of methanol in a volumetric fl ask for 15 min. Aft er fi ltration of the test solution, 5 mL of the fi ltrate was diluted with 100 mL of the same solvent. Samples were analyzed spectrophotometrically (Shimadzu, Japan) at a wavelength of 420 nm.
Zeta potential measurement
Zeta potential (ZP) of the prepared CUR-SPC complex was measured using the dynamic light scatt ering (DLS) technique (Malvern Zetasizer, Malvern Instruments, UK). Samples were dispersed in distilled water and sonicated for 15 min. Aft er sonication, samples were diluted with distilled water (1:10) before measurements.
Curcumin solubility study
An excess quantity of CUR was added to diff erent oils and surfactants in a tightly capped conical fl ask and was constantly agitated at 100 rpm and 37 °C for 24 h in a reciprocating water bath (Bunsen, India). Samples were centrifuged (4000 rpm, 15 min) aft er 24 h equilibrium and aliquots of supernatant were diluted to appropriate concentrations with acetone. The samples were analyzed using a spectrophotometer (Shimadzu, Japan) at a wavelength of 420 nm with acetone as a blank.
Preparation of soft gel fi ll formulations of CUR-SPC complex
According to the lipid formulation classifi cation system, class IIIA was selected to formulate the CUR-SPC complex as soft gel using a hydrophilic surfactant (i.e., HLB > 12) and triglyceride oil. Butylated hydroxy toluene was added as antioxidant to guard against autoxidation of polyoxyethylene moiety for CRM EL or KLX P 124.
Preparation of CUR-SPC complex powder as a fi ll formulation
Dispersion method (20) was applied to prepare lipid fi ll formulations where hydrophilic surfactant was mixed with triglyceride oil for 5 min using a magnetic stirrer (IKA T25, Germany). Prior to encapsulation, CUR phytosomal powder was geometrically mixed with a hydrophilic surfactant/triglyceride blend in a ratio of 1:2 up to formation of a homogenous mass. Compositions of lipid fi ll formulations are shown in Table I .
Preparation of CUR-SPC complex as a semisolid fi ll formulation
CUR and SPC S 100 in a molar ratio of 1:1 were dissolved and refl uxed in 60 mL of dichloromethane for 2 hours. The prepared solution was placed in a controlled temperature water bath adjusted to 45 °C for 4-5 hours up to formation of a semisolid mass. A hydrophilic or lipophilic vehicle was added to the prepared semisolid complex in a 1:1.5 ratio and mixed mechanically at room temperature until formation of a liquefi ed mass. Composition of the lipophilic/hydrophilic vehicles of the CUR-SPC complex semisolid fi ll formulations is shown in Table II . In vitro dissolution studies
In vitro dissolution test was carried out according to USP 32 (21) for CUR capsule dissolution, where 900 mL of 1 % sodium lauryl sulphate (SLS) aqueous solution was used as dissolution medium with the application of apparatus II (Hanson, USA) at 100 rpm. 40 mg of curcumin, curcumin phytosomal powder and diff erent lipid/semisolid fi ll formulations (in terms of CUR) were fi lled in a hard gelatin capsule and att ached to a sinker prior to the start of the dissolution test. Aft er 60 min, a 10 mL aliquot was withdrawn, fi ltered, diluted and analyzed spectrophotometrically at a wavelength of 420 nm.
In vitro dissolution studies of selected formulations were performed in order to obtain the dissolution profi le. Aliquots were withdrawn at time intervals of 30, 60, 120 and 180 min. Samples were diluted and analyzed spectrophotometrically at 420 nm.
Transmission electron microscopy (TEM)
Morphological examination of phytovesicles of the prepared CUR phytosomal powder and some selected CUR-SPC complex formulations was carried out using TEM (model JEM-100S microscope, Jeol, Japan). Samples were diluted with a 0.01 % SLS aqueous solution (1:20) and sonicated for 10 min. A drop of the resultant phospholipid complex dispersions was placed onto a carbon-coated copper grid, leaving a thin liquid fi lm. The fi lm was air-dried and then imaged (22) .
Stability studies
Selected formulations, F9, F10 and F13, were stored in air fi lled soft gelatin capsules for 3 months at 25 °C and 65 % relative humidity. Samples were monitored for any change in the physical state during the storage period. Formulations were assessed for their in vitro dissolution profi le, phytovesicular morphology and ZP before and aft er storage.
RESULTS AND DISCUSSION
Preparation of CUR phytosomes
The CUR-SPC complex was prepared by the method reported by Maiti et al. (10) and Gupta et al. (11) with some modifi cations. Briefl y, CUR and SPC S 100 were refl uxed in a common organic solvent able to solubilize both ingredients for a defi nite time, followed by removal of the organic solvent by a rotary evaporator. Industrially, the mentioned method could not be applied to produce a commercial form of the CUR-SPC complex powder to be used as a dosage form. To produce curcumin phytosomal powder, a very low density powder (Aerosil 200) was selected among diff erent fi llers as the most appropriate fi ller. Solvent was evaporated completely aft er 4-5 hours at 45-50 °C (24) . The complex fl akes formed were mechanically ground to produce a fi ne and fl owable powder.
Analysis of CUR content
Analysis was carried out for total curcuminoids in test samples. Results revealed that the amount of total curcuminoids in the prepared phytosomal powder was 19.06 %. The content of total curcuminoids in the CUR-SPC complex powder depends on the amount of fi ller used in the preparation; 2 parts of Aerosil 200 were used to make the ratio of CUR, SPC and fi ller 1:2:2. The amount of curcuminoids in the CUR-SPC complex powder may be increased by decreasing the amount of fi ller, which requires further examinations.
Measurement of zeta potential (ZP)
The magnitude of zeta potential indicates the degree of electrostatic repulsion between similarly charged particles, which infl uences the stability of colloidal dispersions. Phytosomes carry a negative charge due to the presence of the SPC phosphate group in water environment at neutral pH (25) . Results revealed that ZP of the prepared CUR phytosomes was -35.4 ± 2.45 mV, which indicates good stability. It has been suggested that high absolute ZP values (± 30 mV) may serve as a partial indicator of physical stability to ensure creation of a high energy barrier against rupture or coalescence of the formed globules (26) .
Curcumin solubility study
Saturated solubility of CUR in water could not be detected because of spectrum shift from the wavelength of 420 nm to 280 nm due to its poor stability and decomposition under neutral-basic conditions (23) . CUR solubility studies were carried out in diff erent aqueous and non-aqueous media and the results are shown in Fig. 1 .
CUR solubility in Miglyol 812, soya bean oil and castor oil was 3.56, 2.64 and 0.267 mg g -1 , respectively. Hydrophilic surfactants (CRM EL and KLS P 124) caused a signifi cant increase in saturated solubility of CUR, reaching 41 and 23 mg g -1 , respectively. On the other hand, CUR solubility in PEG and castor oil of 114.6 (7) and 0.267 mg g -1 (8), resp., was reported in the literature. 
Preparation of soft gel fi ll formulations of the CUR-SPC complex
There are many advantages of selecting soft gels as a dosage form for the development of curcumin phytosomal powder, one of them being the ability to increase the dose of CUR in soft gels to 200 mg CUR per capsule compared to only 100 mg CUR per marketed hard gelatin capsule. Another advantage is the use of several bioactive excipients, like poloxamers, PEG, CRM RH 40 and CRM EL, because of their reported inhibitory eff ect on CYP3A4 (27, 28) aff ecting the intestinal metabolism of CUR (29) and hence promoting its systematic bioavailability.
Type IIIA lipid formulation containing hydrophilic surfactant and medium chain triglyceride oil was selected to formulate the CUR-SPC complex powder in soft gels.
Preparation of CUR-SPC complex powder as a soft gel fi ll formulation
Diff erent hydrophilic surfactants were used at diff erent concentrations to optimize the fi ll formulation in order to enhance the CUR dissolution profi le pursuant to pharmacopoeial requirements. The optimum ratio between the CUR-SPC complex powder and oil to be encapsulated in soft gel was found to be 1:2, as seen in F1. CRM EL was used in F2, F3, and F4 at concentrations of 10, 20 and 40 % (m/m), respectively, in the presence of Miglyol 812 as oily vehicle to study the eff ect of diff erent CRM EL concentrations on CUR dissolution. An increase in the fi ll formulation viscosity was observed with the increase of the CRM EL concentration. On the other hand, in the formulation F5, 20 % (m/m) CRM EL was used in the presence of soya bean oil instead of Miglyol 812 to show the eff ect of a diff erent type of oily vehicle on the dissolution rate of CUR-SPC complex powder.
In formulations F6 and F7, CRM RH 40 (20 % (m/m)) was utilized instead of CRM EL to study the eff ect of using another surfactant from the same chemical group with higher HLB value on the dissolution of CUR formulated with diff erent oily vehicles, Miglyol 812 and soya bean oil, respectively.
In formulations F8 and F9, KLS P 124 was used in concentrations of (20 and 40 %, m/m), respectively, with Miglyol 812 to study the eff ect of diff erent concentrations of liquid poloxamer on the dissolution profi le of CUR from the CUR-SPC complex.
Preparation of CUR-SPC complex semisolid fi ll formulations
Utilizing the semisolid form of the CUR-SPC complex is considered to be a new method for the preparation of CUR-SPC complex soft gels. This method provides several advantages over the conventional method, including the use of a liquid vehicle instead of fi llers to fl uidize the semisolid form of the prepared complex, doubling the CUR content in the soft gel up to 200 mg, few preparation steps and minimal equipment, along with a small chance of material loss during the preparation of the soft gel fi ll formulation. To preserve the CUR-SPC complex structure in a fl uidized form, the used liquefi ed vehicle must not aff ect complex integrity, which could be achieved by using either a lipophilic or hydrophilic vehicle with hydrophilic surfactant. Components of CUR-SPC complex semisolid fi ll formulations are shown in Table II .
In vitro dissolution studies
Dissolution profi le of the CUR phytosomal powder failed to achieve pharmacopoeial tolerance and formulation development was required to enhance the CUR dissolution profi le to comply with the pharmacopoeial limits (i.e., not less than 75 % aft er 1 hour in 1 % SLS aqueous solution).
Results of in vitro dissolution studies of soft gel formulations of CUR-SPC complex powder (F1-F9) and CUR-SPC complex semisolid fi ll formulation (F10-F13) are graphically shown in Fig. 2 . Formulation F1 showed relatively low CUR dissolution, reaching only 13 % aft er 60 min, which could be ascribed to the high affi nity of CUR-SPC complex powder towards lipophilic vehicle (pure miglyol oil).
Dissolution was enhanced by increasing the concentration of hydrophilic surfactant (34, 38 and 80 % of CUR dissolved) where 10, 20 and 40 % (m/m) CRM EL was used in the preparation of F2, F3 and F4, respectively. Although formulation F4 gave bett er dissolution results than F2 and F3, it was excluded from further studies due to its high viscosity.
To study the eff ect of diff erent surfactants on the dissolution of the CUR-SPC complex, CRM EL, CRM RH 40 and KLS P 124 were used in formulations F3, F6 and F8, respectively. It was observed that there was no diff erence between 20 % (m/m) CRM EL and 20 % (m/m) CRM RH 40 while using 20 % (m/m) KLS P 124 showed bett er results (56 % of CUR dissolved aft er 60 min). Therefore, higher concentration of KLS P 124 was examined in formulation F9 which gave the highest CUR dissolution, reaching 85 % aft er 60 min, which was acceptable according to USP pharmacopoeial tolerance.
To select the oily vehicle, soybean oil and miglyol oil were examined in formulations with the same type of surfactant and at the same concentrations as shown for using 20 CUR-SPC complex was greatly enhanced when using Miglyol 812 rather than soybean oil; this may be due to bett er solubility of CUR in Miglyol 812 than in soybean oil, as shown in Fig. 1 .
For CUR-SPC complex semisolid fi ll formulations, lipophilic and hydrophilic vehicles were examined as carriers for the prepared complex. Results for lipophilic vehicles showed that using miglyol oil in formulation F10 rendered bett er dissolution behavior than formulations F11 and F12 containing oleic acid and castor oil, respectively. This may be due to the relatively high CUR solubility in Miglyol 812 (3.56 mg g -1 ) compared to oleic acid and castor oil. On the other hand, using PEG 400 and CRM EL as hydrophilic vehicles resulted in the highest dissolution among lipophilic formulations, which could be also att ributed to high CUR solubility in PEG (114.6 mg g -1 ). Based on the above mentioned results, F9, F10 and F13 were selected for further in vitro dissolution and stability studies. Fig. 3 shows CUR dissolution enhancement by preparing its complex with SPC; dissolution of the latt er was further improved in formulations F9, F10 and F13. Encapsulation of the CUR-SPC complex semisolid formulation in soft gels gave bett er dissolution than CUR-SPC complex powder, which could be att ributed to the liquefi ed form of the complex used in our new method of preparation.
Morphological examination of CUR phytosomes
TEM analysis revealed good stability and spherical, self-closed structure of CUR phytosomes in complex formulations (Fig. 4a and 4b) . Complex formulations did not change the amphiphilic properties and water dispersion associated with phospholipids (12). Saraf et al. (30) suggested that upon interaction with water, the hydrophilic heads of phospholipids are oriented in the direction of the water compartment while the lipophilic tails are oriented away from the water, which is in agreement with our fi ndings. TEM micrographs of formulation F13 in Fig. 4c show opaque vesicles with a regular surface, which may be referred to the CUR-SPC complex solubilized in PEG 400. Continuous dynamic movement of solubilized CUR in PEG 400 supported its ability to appear inside the hollow phospholipid structure and gave denser vesicles compared to the prepared phytosome powder (Fig. 4a) . 
Stability studies of CUR-SPC fi ll formulations
As shown in Figs. 5a and b, the dissolution rate of the CUR-SPC complex was sharply decreased aft er 3 months of storage for formulations F9 and F10 compared to time zero, which could be ascribed to limited solubility of CUR in oily vehicles used in the preparation of such formulations as well as to affi nity of SPC towards the oily vehicle, leading to the salting out of CUR. Salting out of CUR may aff ect the integrity of the CUR-SPC complex, leading to a decrease in CUR dissolution.
In contrast, the dissolution profi le of formulation F13, shown in Fig. 5c , did not change aft er 3 months of storage. This may be explained by the compatibility of PEG 400 and the CUR-SPC complex. Thus, the application of PEG 400 as hydrophilic vehicle to formulate the CUR-SPC complex did not aff ect the CUR-SPC complex integrity.
TEM micrographs of formulation F10 support our suggestions about the CUR salting out from the CUR-SPC complex. Fig. 6a shows transparent vesicles with thin irregular membranes (phospholipid layers) and a small black spot in the middle of each vesicle (salted out CUR). These fi ndings support the idea of possible destruction of the CUR-SPC complex, which in turn aff ects the dissolution behavior of formulation F 10. In contrast, no change in phytosome morphology was observed before and aft er 3 months of storage of formulation F13 (Figs. 4c and 6b, respectively) , which is in agreement with the dissolution results.
The integrity of the phytosome in formulation F13 was also confi rmed by zeta potential measurements. No change in ZP was observed for aqueous dispersion of F13 (-38.8 ± 3.48 mV) compared to that for the CUR-SPC complex (-35.4 ± 2.45 mV), which indicates good stability. It is therefore concluded that PEG 400 does not aff ect the CUR-SPC complex a) b) c)
integrity, which is in agreement with the fi ndings obtained by both dissolution studies and TEM analysis. 
